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ABSTRACT
Somatic mutations of the epidermal growth factor receptor often cause resistance 
to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In 
this study, we aimed to identify partner drugs and pathways that can induce cell 
death in combination with gefitinib in NSCLC cells. We undertook a genome-wide 
RNAi screen to identify synthetic lethality with gefitinib in tyrosine kinase inhibitor 
resistant cells. The screening data were utilized in different approaches. Firstly, we 
identified PRKCSH as a candidate gene, silencing of which induces apoptosis of NSCLC 
cells treated with gefitinib. Next, in an in silico gene signature pathway analysis of 
shRNA library data, a strong correlation of genes involved in the CD27 signaling 
cascade was observed. We showed that the combination of dasatinib (NF-κB pathway 
inhibitor) with gefitinib synergistically inhibited the growth of NSCLC cells. Lastly, 
utilizing the Connectivity Map, thioridazine was identified as a top pharmaceutical 
perturbagen. In our experiments, it synergized with gefitinib to reduce p-Akt levels 
and to induce apoptosis in NSCLC cells. Taken together, a pooled short-hairpin library 
screen identified several potential pathways and drugs that can be therapeutic targets 
for gefitinib resistant NSCLC. 
INTRODUCTION 
Initial broad-based clinical studies found that only 
a minority of individuals with non-small cell lung cancer 
(NSCLC) responded to either gefitinib or erlotinib, which 
are tyrosine kinase inhibitors (TKIs) blocking activation 
of the epidermal growth factor (EGFR) [1-4]. Asian, non-
smoking females were noted to be particularly sensitive 
to this class of drugs [2, 5]. Subsequently, investigators 
discovered that sensitivity to these TKIs was correlated 
with the presence of somatic mutations that affect the 
kinase domain of EGFR, especially either deletions 
within exon 19 or a L858R mutation in exon 21 [6-8]. 
Individuals with these tumors often respond to TKI 
therapy, but usually have progressive disease after 6-12 
months of therapy. These resistant tumors frequently 
acquired either an additional mutation (T790M) in exon 20 
of EGFR or a second mutation in the downstream pathway 
of EGFR, both resulting in lack of response to EGFR-TKI 
[9-11]. Other mechanisms of resistance include either 
amplification of c-met [12, 13] or deletion of PTEN [14, 
15]. A major therapeutic priority is to identify drugs that 
can reverse the TKI resistance in exon 20 mutant EGFR. In 
order to discover additional drugs and pathways that might 
inhibit growth of NSCLC with an exon 20 mutant EGFR, 
we screened with a short-hairpin library for synergism 
with gefitinib [16-20] and identified several molecular 
biological pathways and pharmaceutical compounds that 
inhibited these TKI-resistant NSCLC cells. 
RESULTS 
The focus of our study was to identify target 
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Fig.1: PRKCSH knockdown cells have increased sensitivity to gefitinib. (A) MTT assay was performed using H1975 
NSCLC cells [TKI-resistant, EGFR exon 20 (T790M) and exon 21 mutation] and PC14 NSCLC cells [TKI-sensitive, EGFR exon 19 
(delE746-A750)]. Cells were treated with either vehicle or 10 μM gefitinib for 3 days. Data represent the mean and SD of experiments 
done in triplicate. (B) H1975 cells were cultured with either vehicle or 10 μM gefitinib after transduction with either a non-target siRNA 
or gene-specific siRNA. Relative cell viability (vehicle – gefitinib) / non-target siRNA vehicle x 100 % was measured. (C) H1975 NSCLC 
with stable silencing of PRKCSH (see panel E) were cultured for 3 days either with or without gefitinib (10 μM) and cell proliferation 
was measured (MTT assay). (D) H1975 NSCLC cells either with or without stable silencing of PRKCSH (see panel E) were cultured for 
6 days either with or without gefitinib (10 μM) and total cell death [apoptosis and necrosis (Annexin V+)] (%) was measured. (E) H1975 
NSCLC cells transduced with either a non-target shRNA or a stable PRKCSH shRNA were cultured with either 5 or 10 μM gefitinib for 24 
hours. Lysates were western blotted and probed with antibodies against either PRKCSH, PARP, cleaved PARP, caspase 9, cleaved caspase 
9, caspase 3, cleaved caspase 3 and GAPDH (loading control). Densitometry of bands of cleaved PARP, cleaved caspase 9, cleaved caspase 
3 and GAPDH was performed with image J software. Band intensities were normalized to GAPDH band intensity. * p < 0.05, ** p value 
< 0.01. 
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genes and/or agents that can overcome TKI-resistance 
in NSCLC. Initial growth curves (MTT assays) showed 
that H1975 NSCLC cells [TKI-resistant, harbors EGFR 
exon 20 (T790M) and exon 21 (L858R) mutations] was 
more resistant to gefitinib than PC14 cells [TKI-sensitive, 
EGFR exon 19 (delE746-A750)] (Fig. 1A). A screen was 
conducted for genes that, when silenced, enhanced TKI 
sensitivity in H1975 cells. The cells were transduced 
with a small hairpin RNAs (shRNAs) pooled library and 
a synthetic lethality screen in the presence of gefitinib 
was performed. Hairpins targeting 35 genes (from 16,000 
genes) reproducibly conferred gefitinib sensitivity in 
H1975 cells (threshold relative fold depletion in gefitinib 
versus vehicle as log2 ratio and p-value < 0.05; Table 1). 
Twenty genes from the initial 35 target genes 
identified in the primary screen were examined for their 
growth inhibitory effects in gefitinib treated H1975 cells 
using independent siRNAs. Five genes (SIRT3, PRKCSH, 
REP15, MKRN1, KIAA0323) were confirmed to enhance 
the gefitinib-induced inhibition of cell proliferation (Fig. 
1B). Silencing the PRKCSH gene produced the most 
profound growth inhibition. Therefore, expression of 
the PRKCSH gene was stably silenced in H1975 cells 
using lentiviral shRNA vector which markedly enhanced 
the gefitinib-related growth inhibition (50% decrease 
compared to gefitinib alone) and apoptosis (27% versus 
17% with gefitinib alone) (Figs. 1C, D). Silencing of 
PRKCSH enhanced the expression of cleaved PARP, 
caspase-9 and -3 which was only slightly enhanced by 
addition of gefitinib (5, 10 μM) (Fig. 1E). 
We next investigated which pathways were linked 
to gefitinib-induced cell death based on shRNA library 
data using NCI / Nature Pathway Interaction Database 
(PID) (http://pid.nci.nih.gav) (Table 2) [21]. The CD27 
signaling pathway (including BCL2L1, MAP3K7, 
MAP3K10, MAPK10, TRAF5, IKBKB) was identified as 
the most significantly affected (p-value: 9.3325 E-05; Fig. 
2, Table 2). This pathway relates to activation of NF-κB 
and pro-survival signaling. To explore the role of NF-κB 
pathway in gefitinib-induced cell death, cells were treated 
with dasatinib. Dasatinib is a known inhibitor of multiple 
tyrosine kinases (BCR-ABL, SRC family, c-Kit etc) which 
inhibits the NF-κB pathway upstream of Src pathway [22, 
23]. 
Fig.2: Three different approaches to identify a pathway or drug that can overcome gefitinib resistance of NSCLC. 
H1975 cells were transduced with shRNA pooled library (MISSION® shRNA) and a synthetic lethality screen with gefitinib was performed. 
shRNA library data were statistically analyzed by RIGER software (left panel). “Heat-map”: red and green represent either accumulation 
or depletion of the shRNA, respectively, when comparing the gefitinib treated and untreated cohort of H1975 NSCLC cells. Arrows 
point to those shRNA vectors whose abundance was significantly changed compared to control. Pathway analysis of the shRNA screen 
was done using NCI / Nature Pathway Interaction Database (PID) (middle panel). Connectivity Map software (right panel) was used to 
identify small-molecule combination therapy with gefitinib based on shRNA library data. All three approaches found effective combination 
treatment with gefitinib. 
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Fig.3: Combination of dasatinib and gefitinib synergistically inhibited cell proliferation of TKI-resistant H1975 
NSCLC cells. (A) Co-treatment with gefitinib (10 μM) and dasatinib (400 nM) for 3 days inhibited growth of H1975 cells greater than 
either inhibitor alone (MTT assays, mean ± SD of 3 experiments done in quadruplicate). (B) H1975 cells were cultured with gefitinib 
(10 μM), dasatinib (400 nM) and combination (gefitinib 10 μM, dasatinib 400 nM) for 6 days; cells were harvested and stained with 
Annexin-V and PI, and analyzed by flow cytometry. Cells in lower right quadrant (Annexin-V+/PI-) was defined as apoptotic cells and 
upper right quadrant (Annexin-V+/PI+) was defined as necrotic cells. Total cell death (%) [apoptotic cells and necrotic cells] was measured. 
Representative results are shown. (C) H1975 cells were exposed to gefitinib alone (5 μM or 10 μM), dasatinib alone (100, 200 or 400 nM) 
and combination treatment gefitinib (5 μM or 10 μM) and dasatinib (100, 200 or 400 nM) for 3 days. Combination treatment inhibited 
growth of H1975 cells greater than either inhibitor alone. Combination effect was measured by Calcuysin software. CI < 1, CI = 1 and 
CI > 1 represent synergism, additive, and antagonism of the two compounds, respectively. (D) H1975 cells were exposed to gefitinib (10 
μM), dasatinib (400 nM) and combination (gefitinib 10 μM and dasatinib 400 nM) for 24 hours. Lysates were western blotted and probed 
with antibody against PARP, cleaved PARP, Src, phospho-Src, caspase 3, cleaved caspase 3 and GAPDH (loading control). Densitometry 
of bands of cleaved PARP, phospho-Src, cleaved caspase 3 and GAPDH was done with image J software, and band intensities were 
normalized to GAPDH band intensity. * p < 0.05, ** p value < 0.01. 
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Treatment of cells with dasatinib promoted gefitinib-
induced cell inhibition of proliferation of NSCLC (Fig. 
3A). Dasatinib treatment alone did not have a potent 
ability to induce cell death of H1975 cells; but when 
combined with gefitinib, they significantly increased cell 
death (Fig. 3B). Our studies using multiple concentration 
of gefitinib and dasatinib showed that co-treatment with 
gefitinib (5 or 10 μM) and dasatinib (100, 200 or 400 nM) 
synergistically inhibited growth of H1975 cells (CI<1 1-6 
columns, Fig. 3C). Also, in contrast to either drug alone, 
this drug combination induced apoptosis, as shown by 
an increase in caspase 3 cleavage (Fig. 3D). Exposure to 
dasatinib attenuated phospho-Src, as well as phospho-Rel 
A (Fig. 3D). 
In-silico screening using the Connectivity Map 
of our shRNA library data identified drugs that could 
enhance cell kill by gefitinib (Overview, Fig. 2). In 
brief, this correlation-based pattern-matching software 
utilizes the input gene signatures from our shRNA library 
analysis by RIGER. Based on the degree of difference 
between gefitinib and the pharmaceutical perturbagen, 
a connectivity score is assigned, and the negative 
enrichment score is used to identify a perturbagen inducing 
a synergistic effect with gefitinib (Table 3). The top 
pharmaceutical compounds were examined. Surprisingly, 
the first compound on the list was “thioridazine”, which 
has been reported to have antiproliferative activity 
against tumor cells [24]. Exposure of H1975 cells to 
either thioridazine (10 μM) or gefitinib (10 μM) treatment 
produced an approximate 25% growth inhibition; when the 
two drugs were combined, an appropriate 65% decreased 
growth occurred (Fig. 4A). Similarly, the combination of 
the two drugs caused cell death (annexin V/propidium 
iodine positivity) of about 40% of the lung cancer 
cells (H1975) compared to either gefitinib (10 μM) or 
thioridazine (15 μM) alone (~ 12% and 14%, respectively) 
(Fig. 4B). Furthermore, co-treatment with thioridazine and 
gefitinib for 3 days synergistically inhibited the growth of 
the lung cancer cells (CI<1, columns labeled 1-4; (Fig. 
4C,). Thioridazine (10 μM) and gefitinib (10 μM) alone 
(24 hours) did not affect expression of either p-Akt or 
p-p70S6K in lung cancer cells; but together, they reduced 
levels of these activated signaling pathways (Fig 4D). 
DISCUSSION 
Almost all patients with a newly diagnosed NSCLC 
with either an exon 19 or 21 mutation of EGFR have an 
initial response to TKI therapy. However, invariably after 
6-12 months, the tumor becomes resistant to therapy, 
associated with additional genomic changes especially a 
T790M EGFR mutation. Similar to the lessons learned 
with HIV therapy, treatment of these NSCLC with more 
than one drug may prevent emergence of a drug-resistant 
clone. Therefore, we performed a synthetic lethality screen 
with gefitinib using a pooled short-hairpin RNA library 
in NSCLC cells to help identify pathways druggable in 
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Fig.4: Effect of the combination of thioridazine and gefitinib on TKI-resistant NSCLC cells. (A) Incubation with gefitinib 
(10 μM) and thioridazine (10 μM) for 3 days inhibited growth (MTT assay) of H1975 NSCLC cells greater than either inhibitor alone 
(MTT assays, mean ± SD of 3 experiments done in quadruplicate). (B) H1975 NSCLC cells were exposed to either gefitinib (10 μM) 
or thioridazine (10 μM), or their combination (gefitinib 10 μM, thioridazine 10 μM) for 6 days; cells were harvested and stained with 
Annexin-V and PI, and analyzed by flow cytometry. Lower right quadrant (Annexin-V+/PI-) was defined as apoptotic cells and upper right 
quadrant (Annexin-V+/PI+) was defined as necrotic cells. Total cell death (%) [apoptotic cells and necrotic cells] is displayed graphically. 
Representative results are shown. (C) Incubation with gefitinib (10 μM or 15 μM) and/or thioridazine (10 μM or 15 μM) for 3 days inhibited 
growth of H1975 cells measured in MTT assay (top of panel C). Combination effect was measured by Calcuysin software. CI < 1, CI = 1 
and CI > 1 represent synergism, additive, and antagonism of the two compounds, respectively. (D) H1975 cells were cultured with either 
gefitinib (10 μM) and/or thioridazine (10 μM) for 24 hours. Lysates were western blotted and probed with antibody against, pan-Akt, 
phospho-Akt, p70S6K, phospho-p70S6K and GAPDH (loading control). Densitometry of bands of phospho-Akt,, phospho-p70S6K, and 
GAPDH was done with image J software. Band intensities were normalized to GAPDH band intensity. * p < 0.05, ** p value < 0.01. 
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TKI resistant NSCLC. Furthermore, the shRNA library 
data was used for gefitinib-related pathway analysis and 
in-silico gene signature based examination. 
From the shRNA library screen and siRNA 
validation experiments in NSCLC cells, we identified and 
validated PRKCSH as a candidate gene that synergizes 
with gefitinib (Fig. 1). PRKCSH encodes the non-
catalytic β-subunit of glucosidase II (GIIβ). Glucosidase 
II facilitates protein translocation and “quality control” 
pathways of the endoplasmic reticulum (ER). Mutation of 
this gene is associated with autosomal dominant polycystic 
liver disease (PCLD) [25-27]. Silencing of PRKCSH 
in NSCLC cells caused decreased cell proliferation 
and increase in the proportion of apoptotic cells, and 
when combined with gefitinib both these effects were 
significantly enhanced (Figs. 1C and D). Identification 
of PRKCSH led us to examine PKD2 [28-30]. Both 
these molecules are involved in autosomal dominant 
polycystic kidney and liver diseases, and PRKCSH 
acts as a chaperone-like molecule to regulate PKD2 
expression. PKD2 controls the endoplasmic reticulum 
(ER) regulated Ca2+ mediated apoptosis by decreasing the 
Ca2+ concentration in the ER [26]. Silencing of PKD2 in 
NSCLC cells augmented apoptosis when combined with 
gefitinib (Supplement Fig. 1B, C). In addition, PKD2 
knockdown inhibited activation of the ERK pathway, 
which is associated with cell survival (Supplement Fig. 
1C). To the best of our knowledge, neither PRKCSH 
nor PKD2 has been reported as therapeutic targets for 
NSCLC. The use of either PRKCSH or PKD2 inhibitors 
in combination with gefitinib to treat NSCLC requires 
further study. 
Our shRNA library screen also identified the CD27 
signaling pathway which relates to activation of NF-κB 
and pro-survival signals (Fig. 2 and Table 2). Dasatinib 
can modulate the NF-κB pathway; but alone, the drug had 
little effect on either apoptosis or proliferation of NSCLC. 
However, the combination of dasatinib and gefitinib 
synergistically induced cell death and inhibited cell growth 
(Fig. 3). Taken together, these experiments suggest that 
the combination of NF-κB inhibitors and gefitinib may be 
therapeutically effective for EGFR-mutant NSCLC. 
The Connectivity Map is a genomic screening 
tool for linking genes associated with a selected 
phenotype with potential therapeutic agents [31, 32]. 
To discover additional therapeutic compounds that may 
synergistically interact with gefitinib, the shRNA library 
data were analyzed using the Connectivity Map software. 
Thioridazine, a phenothiazine derivative, was one of the 
prominent “hits”. Several reports have noted that the drug 
can have anticancer activity [33-35]. The mechanism by 
which this is mediated is unclear, although it may occur 
by inhibiting the PI3K/Akt pathway. The combined 
treatment of thioridazine and gefitinib synergistically 
inhibited proliferation of NSCLC cells (Fig. 4C). Neither 
thioridazine nor gefitinib suppressed levels of activated 
Akt and p70S6K in NSCLC, but their combination 
reduced phospho-Akt and phospho-p70S6K levels in 
these cells (Figure 4D). Phenothiazines can cause severe 
extrapyramidal side-effects such as tardive dyskinesia. 
Thus, further modification of this molecule should be 
explored to incorporate the anti-NSCLC effects without 
neurological toxicity. Alternatively, phenothiazines 
activate PP2A; we (unpublished data) and others [36] 
have shown that drugs that activate PP2A have anti-
cancer activity. Novel activators of this phosphatase may 
synergize with gefitinib to inhibit growth of EGFR mutant 
NSCLC. 
In summary, shRNA library screen identified 
therapeutic partners of gefitinib for treatment of EGFR 
mutant NSCLC including EGFR T790M. Furthermore, the 
shRNA library data were utilized for gene signature based 
in-silico query which identified PRKCSH as an interesting 
partner with gefitinib. Finally, the shRNA results were 
used to interrogate the Connectivity Map. This pathway 
analysis identified thioridazine as a synergistic partner 
of gefitinib. In summary, this study using several 
experimental approaches has identified exciting drugs and 
pathways for further study in EGFR mutant NSCLC. 
MATERIALS AND METHODS 
Reagents and NSCLC cell lines 
The following compounds were used in this study: 
gefitinib; dasatinib [LC Laboratories (MA, USA)]; 
thioridazine (10-[2-(1-methyl-2-piperidyl) ethyl]-2-
methylthio-phenothiazine) [Sigma Aldrich (Singapore)]. 
All reagents were dissolved in dimethyl sulfoxide (DMSO) 
and the final concentration of DMSO never exceeded 0.1% 
in culture. Antibodies: Akt [36], phospho-Akt (Ser473), 
caspase-3, 8, 9, cleaved caspase-3, 8, 9, ERK, phospho-
ERK, IκBα, phospho-IκBα, p70S6K, phospho-p70S6K 
(Thr421 / Ser424), PKD2, PRKCSH, PARP, cleaved-
PARP, RelA, phospho-RelA, Src, phospho-Src, GAPDH 
were purchased from Cell Signaling (MA, USA). 
The human NSCLC cell lines H1975 and PC14 were 
purchased from the American Type Culture Collection 
(Manassas,VA). These cells were cultured in RPMI 1640 
supplemented with 10% fetal calf serum, 100 U/ml of 
penicillin, and 100 μg/ml of streptomycin. The H1975 cell 
line has an EGFR T790M mutations in exon 20, associated 
with gefitinib and erlotinib resistance. The PC14 cell 
line has an EGFR delE746-A750 mutation in exon 19, 
associated with TKI sensitivity.
Pooled short-hairpin RNA library screen 
H1975 cells were transduced in quadruplicates with 
a pooled shRNA library (MISSION® shRNA), consisting 
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of 80,000 hairpins targeting 16,000 genes at an MOI of 0.3 
hairpins/cell. After 48 hours, puromycin was added to the 
media (5 μg/ml) to select for transduced cells. 
Puromycin was continuously in the media until cells 
were harvested. Following selection, each replicate was 
treated with either vehicle or gefitinib (8 μM) for 1 week. 
This concentration of gefitinb was identified as the IC50 to 
H1975 cells [37]. Cells were harvested and genomic DNA 
was isolated both prior to drug treatment and at day 10. 
shRNA sequences were amplified by PCR using specific 
primers. The purified PCR products were subjected to 
high-throughput sequencing using Illumina Genome 
Analyzer IIx. The quality of the data was checked, 
normalized and statistically analyzed by RNAi gene 
enrichment ranking (RIGER) software [38]. Significant 
hits were defined as those altered by 2 fold, p<0.05
PRKCSH and PKD2 knockdown cells 
Stably knockdown of the expression of the 
PRKCSH and PKD2 genes in H1975 cells used lentiviral 
shRNA vectors. PRKCSH shRNA plasmid was kindly 
provided by Prof. Gard Walz (Renal Division, University 
Hospital Freiburg). The PRKCSH shRNA sequence 
(5’-CCGGAAGTTCAGTGCCATGAAGTATCT 
CGAGATACTTCATGGCACTGAACTTTT TTTG-3’) 
was cloned into pLKO.1 vector. PKD2 shRNA plasmid 
was constructed according to selected sequences within 
the gene and cloned into pLKO.1 vector. (5’-CCGGC
ACGACCAACAGATACTATCTCGAGATAGTATC
TGTTGGTCGTGTTTTTG -3’). The negative control 
shRNA [SHC002 (MISSION® shRNA)] was purchased 
from Sigma. Cells were transduced and selected with 
puromycin (2 μg / ml, 10 days). Silencing of the genes 
were confirmed by western blotting. 
Cell proliferation assays 
NSCLC cells were seeded at a density of 10,000 per 
well in 96-well plates. After 24 hours, these cells were 
cultured with multiple concentrations of drugs for 72 
hours. Cell proliferation was determined using CellTiter 
96® Non-Radioactive Cell Proliferation Assay (Promega) 
according to the manufacturer’s instructions; and the 
plates were read by a fluorescence spectrometer. Half-
maximal inhibitory concentrations (“IC50-values”) were 
determined from the images under the growth inhibition 
curves using Prism 4.0 software. Calcusyn software 
(Biosoft) was used to analyze combination drug treatment 
data. CI<1, CI=1 and CI>1 represent synergism, additive, 
and antagonism of the two compounds, respectively (Fig. 
3C, Fig. 4C)
 Cell death assays 
Cells were harvested and stained with Annexin-V 
and PI (BD Biosciences), and analyzed by a FACSCalibur 
flow cytometer (BD Sciences). Lower right quadrant 
(Annexin-V+/PI-) and upper right quadrant (Annexin-V+/
PI+) were defined as apoptotic cells and necrotic cells, 
respectively. 
Western blot analysis 
Cells were harvested, washed with PBS, and 
lysed in ProteoJET Mammalian Cell Lysis Regent 
(Fermentas) supplemented with ProteoBlock Protease 
Inhibitor Cocktail (Fermentas). Protein concentrations 
were measured by Bradford assay (Bio-Rad, Richmond, 
CA). Equal amounts of protein were dissolved in SDS-
polyacrylamide gel electrophoresis sample loading 
buffer and electrophoresed in a polyacrylamide gel 
(7.5% or 10%). After electrophoresis, the proteins were 
electrotransferred to a polyvinylidene difluoride membrane 
(Immobilon, Millipore, Bedford, MA). Immunoblotting 
was performed using antibodies mentioned above, and 
detected by ECL-Plus reagent (Amersham, Boston, MA). 
Statistical analysis 
Data were collected using a minimum of three 
experiments and used to calculate the mean ± S.D. 
Statistical significance was calculated using either 
ANOVA or student-t test and was considered significant 
at p values < 0.05. 
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